The U.S. Food and Drug Administration (FDA) is taking a significant step in drug safety by reviewing an artificial intelligence-based tool designed to predict drug-induced liver damage. This innovative tool, a digital liver model, has been accepted into the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program.

Improving Drug Safety

Drug-induced liver damage is a leading cause of drug trial failures, and current methods often fall short in accurately predicting human risk. The AI-driven tool aims to enhance early safety assessments by comparing the chemical structures of new small-molecule drugs with those of existing medicines that have known safety profiles. This could lead to more informed decisions before human trials begin and reduce reliance on animal testing.

Michael Davis, the acting director of the FDA’s Center for Drug Evaluation and Research (CDER), emphasized the potential of new technologies to streamline drug development and ultimately improve patient care. The acceptance of the tool marks the first step in a multi-stage qualification process that, if successful, would allow drugmakers to use it in regulatory submissions.

Regulatory Pathway

The FDA’s Drug Development Tool qualification program collaborates with developers to guide tools for specific uses. The letter of intent accepted by the FDA is the initial submission stage, determining whether a tool will be accepted into the program. This initiative reflects the FDA’s commitment to fostering innovation in drug development while maintaining rigorous safety standards.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.